Merus Labs International (MSL.TO) 3.19 $MSL.TO
Post# of 273322
Posted On: 07/29/2015 1:41:24 PM
Merus Labs International (MSL.TO) 3.19 $MSL.TO
Merus Labs Announces Record Q1 2015 Results
Marketwire Canada - Wed Feb 11, 3:00PM CST
Merus Labs International Inc. ("Merus" or the "Company"
(TSX:MSL)(NASDAQ:MSLI) is pleased to announce today its financial results for its first quarter of fiscal year 2015.
MSL.TO: 3.19 (+0.03), MSLI: 2.48 (+0.02)
Merus Labs Appoints Geoff Morrow as Vice President, Business Development
Marketwired - Wed Feb 04, 7:03AM CST
Merus Labs International Inc. (TSX: MSL)(NASDAQ: MSLI) ("Merus" or "the Company" today announced the appointment of Geoff Morrow as Vice President, Business Development.
MSL.TO: 3.19 (+0.03), MSLI: 2.48 (+0.02)
Merus Labs International Inc. Announces Results for Fiscal 2014
Marketwire Canada - Thu Dec 18, 3:00PM CST
Merus Labs International Inc. ("Merus" or the "Company" (TSX:MSL)(NASDAQ:MSLI) is pleased to announce today its financial results for its fiscal year 2014.
MSL.TO: 3.19 (+0.03), MSLI: 2.48 (+0.02)
Merus Labs International Inc. Appoints Barry Fishman as Chief Executive Officer
Marketwired - Mon Dec 15, 2:00PM CST
The Board of Directors of Merus Labs International Inc. ("Merus" or the "Company" (TSX: MSL)(NASDAQ: MSLI) is pleased to announce the appointment of Mr. Barry Fishman as CEO, effective today. Mr. Fishman has been serving as interim CEO since September 23, 2014.
MSL.TO: 3.19 (+0.03), MSLI: 2.48 (+0.02)
Merus Labs International Inc. Announces Normal Course Issuer Bid
Marketwire Canada - Mon Nov 17, 7:00AM CST
Merus Labs International Inc. ("Merus" or the "Company" (TSX:MSL)(NASDAQ:MSLI) announced today that it is proceeding with a normal course issuer bid for up to 7,615,972 common shares of the Company, representing approximately 10% of the total public float of the common shares of the Company. On November 12, 2014, the Company had a total of 81,245,724 common shares outstanding out of which a total of 5,086,000 common shares are non-public shares held by directors and senior officers or held in escrow. The Company has received approval from the Toronto Stock Exchange (the "TSX" to commence this bid on November 19, 2014. Purchases will be made on the TSX at the market price at the time of acquisition. Pursuant to TSX policies, daily purchases will not exceed 149,025 common shares except where such purchases are made in accordance with "block purchases" exemptions under applicable TSX policies.
MSL.TO: 3.19 (+0.03), MSLI: 2.48 (+0.02)
Merus Labs Announces Management & Board Changes
Marketwire Canada - Tue Sep 23, 6:30AM CDT
Merus Labs International Inc. ("Merus" or the "Company" (TSX:MSL)(NASDAQ:MSLI) today announced that Mr. Elie Farah has resigned as CEO and as a member of the Merus Board to pursue other opportunities. The Board of Directors thanks Mr. Farah for his contribution to building a strong foundation and platform for growth for the Company and wishes him well in his future endeavors.
MSL.TO: 3.19 (+0.03), MSLI: 2.48 (+0.02)
Merus Labs International Inc. Announces Acquisition of Sintrom(R)
Marketwire Canada - Mon Sep 08, 7:30AM CDT
Merus Labs International Inc. ("Merus" or the "Company" (TSX:MSL)(NASDAQ:MSLI) is pleased to announce that one of its wholly owned subsidiaries has acquired from Novartis AG ("Novartis", in certain European countries, the rights to manufacture, market, and sell the branded prescription medicine product Sintrom(R) (acenocoumarol). Acenocoumarol is an anticoagulant indicated for the treatment and prevention of thromboembolic diseases. Sintrom(R) has been available in Europe for over 50 years and in calendar year 2013 the product had net sales of approximately US$28 million in the territories acquired.
MSL.TO: 3.19 (+0.03), MSLI: 2.48 (+0.02), NVS: 103.78 (+0.99)
Merus Labs International Inc. Announces Completion of $7 Million Financing Transaction With Dacha Strategic Metals Inc.
Marketwire Canada - Thu Aug 14, 2:29PM CDT
Merus Labs International Inc. ("Merus" or the "Company" (TSX:MSL)(NASDAQ:MSLI) is pleased to announce that, further to its news release dated July 4, 2014, the Company has today completed the financing acquisition transaction with Dacha Strategic Metals Inc. ("Dacha". The Company issued 4,246,544 common shares to Dacha in exchange for all of the issued and outstanding shares of a newly incorporated subsidiary ("Newco" incorporated by Dacha for the completion of the transaction. Newco held $6,975,001 in cash and had no other assets or liabilities upon completion of the Acquisition.
MSL.TO: 3.19 (+0.03), MSLI: 2.48 (+0.02)
Merus Labs International Inc. Subsidiary Signs Product Acquisition Letter of Intent
Marketwire Canada - Thu Aug 07, 3:00PM CDT
Merus Labs International Inc. ("Merus" or the "Company" (TSX:MSL)(NASDAQ:MSLI) is pleased to announce today that one of its wholly owned subsidiaries has signed a letter of intent to acquire the rights to manufacture, market, and sell a branded prescription medicine product in certain European countries. The product is being divested by a large multinational pharmaceutical company. In the calendar year 2013, the product had net sales of approximately US$28 million in the applicable European territories.
MSL.TO: 3.19 (+0.03), MSLI: 2.48 (+0.02)
Merus Labs Announces Record Q1 2015 Results
Marketwire Canada - Wed Feb 11, 3:00PM CST
Merus Labs International Inc. ("Merus" or the "Company"
(TSX:MSL)(NASDAQ:MSLI) is pleased to announce today its financial results for its first quarter of fiscal year 2015. MSL.TO: 3.19 (+0.03), MSLI: 2.48 (+0.02)
Merus Labs Appoints Geoff Morrow as Vice President, Business Development
Marketwired - Wed Feb 04, 7:03AM CST
Merus Labs International Inc. (TSX: MSL)(NASDAQ: MSLI) ("Merus" or "the Company"
today announced the appointment of Geoff Morrow as Vice President, Business Development. MSL.TO: 3.19 (+0.03), MSLI: 2.48 (+0.02)
Merus Labs International Inc. Announces Results for Fiscal 2014
Marketwire Canada - Thu Dec 18, 3:00PM CST
Merus Labs International Inc. ("Merus" or the "Company"
(TSX:MSL)(NASDAQ:MSLI) is pleased to announce today its financial results for its fiscal year 2014. MSL.TO: 3.19 (+0.03), MSLI: 2.48 (+0.02)
Merus Labs International Inc. Appoints Barry Fishman as Chief Executive Officer
Marketwired - Mon Dec 15, 2:00PM CST
The Board of Directors of Merus Labs International Inc. ("Merus" or the "Company"
(TSX: MSL)(NASDAQ: MSLI) is pleased to announce the appointment of Mr. Barry Fishman as CEO, effective today. Mr. Fishman has been serving as interim CEO since September 23, 2014. MSL.TO: 3.19 (+0.03), MSLI: 2.48 (+0.02)
Merus Labs International Inc. Announces Normal Course Issuer Bid
Marketwire Canada - Mon Nov 17, 7:00AM CST
Merus Labs International Inc. ("Merus" or the "Company"
(TSX:MSL)(NASDAQ:MSLI) announced today that it is proceeding with a normal course issuer bid for up to 7,615,972 common shares of the Company, representing approximately 10% of the total public float of the common shares of the Company. On November 12, 2014, the Company had a total of 81,245,724 common shares outstanding out of which a total of 5,086,000 common shares are non-public shares held by directors and senior officers or held in escrow. The Company has received approval from the Toronto Stock Exchange (the "TSX" to commence this bid on November 19, 2014. Purchases will be made on the TSX at the market price at the time of acquisition. Pursuant to TSX policies, daily purchases will not exceed 149,025 common shares except where such purchases are made in accordance with "block purchases" exemptions under applicable TSX policies. MSL.TO: 3.19 (+0.03), MSLI: 2.48 (+0.02)
Merus Labs Announces Management & Board Changes
Marketwire Canada - Tue Sep 23, 6:30AM CDT
Merus Labs International Inc. ("Merus" or the "Company"
(TSX:MSL)(NASDAQ:MSLI) today announced that Mr. Elie Farah has resigned as CEO and as a member of the Merus Board to pursue other opportunities. The Board of Directors thanks Mr. Farah for his contribution to building a strong foundation and platform for growth for the Company and wishes him well in his future endeavors. MSL.TO: 3.19 (+0.03), MSLI: 2.48 (+0.02)
Merus Labs International Inc. Announces Acquisition of Sintrom(R)
Marketwire Canada - Mon Sep 08, 7:30AM CDT
Merus Labs International Inc. ("Merus" or the "Company"
(TSX:MSL)(NASDAQ:MSLI) is pleased to announce that one of its wholly owned subsidiaries has acquired from Novartis AG ("Novartis", in certain European countries, the rights to manufacture, market, and sell the branded prescription medicine product Sintrom(R) (acenocoumarol). Acenocoumarol is an anticoagulant indicated for the treatment and prevention of thromboembolic diseases. Sintrom(R) has been available in Europe for over 50 years and in calendar year 2013 the product had net sales of approximately US$28 million in the territories acquired. MSL.TO: 3.19 (+0.03), MSLI: 2.48 (+0.02), NVS: 103.78 (+0.99)
Merus Labs International Inc. Announces Completion of $7 Million Financing Transaction With Dacha Strategic Metals Inc.
Marketwire Canada - Thu Aug 14, 2:29PM CDT
Merus Labs International Inc. ("Merus" or the "Company"
(TSX:MSL)(NASDAQ:MSLI) is pleased to announce that, further to its news release dated July 4, 2014, the Company has today completed the financing acquisition transaction with Dacha Strategic Metals Inc. ("Dacha". The Company issued 4,246,544 common shares to Dacha in exchange for all of the issued and outstanding shares of a newly incorporated subsidiary ("Newco" incorporated by Dacha for the completion of the transaction. Newco held $6,975,001 in cash and had no other assets or liabilities upon completion of the Acquisition. MSL.TO: 3.19 (+0.03), MSLI: 2.48 (+0.02)
Merus Labs International Inc. Subsidiary Signs Product Acquisition Letter of Intent
Marketwire Canada - Thu Aug 07, 3:00PM CDT
Merus Labs International Inc. ("Merus" or the "Company"
(TSX:MSL)(NASDAQ:MSLI) is pleased to announce today that one of its wholly owned subsidiaries has signed a letter of intent to acquire the rights to manufacture, market, and sell a branded prescription medicine product in certain European countries. The product is being divested by a large multinational pharmaceutical company. In the calendar year 2013, the product had net sales of approximately US$28 million in the applicable European territories. MSL.TO: 3.19 (+0.03), MSLI: 2.48 (+0.02)
(0)
(0)